PT  - JOURNAL ARTICLE
AU  - Tavares, Leticia Camargo
AU  - Muralitharan, Rikeish R.
AU  - Snelson, Matthew
AU  - Marques, Francine Z.
TI  - Rare pathogenic variants in G-protein coupled receptor genes involved in gut-to-host communication are associated with cardiovascular disease risk
AID  - 10.1101/2024.10.01.24314734
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.01.24314734
4099  - http://medrxiv.org/content/early/2024/10/02/2024.10.01.24314734.short
4100  - http://medrxiv.org/content/early/2024/10/02/2024.10.01.24314734.full
AB  - Background Gut microbial metabolites called short-chain fatty acids (SCFA) confer protective effects against cardiovascular disease and high blood pressure. Proposed mechanisms include anti-inflammatory signalling mediated by SCFA-sensing G-protein-coupled receptors (GPCR), particularly GPR41, GPR43, and GPR109a, as suggested by knockout mouse models. We aimed to determine if rare pathogenic variants (RPVs) affecting GPCR genes in humans increase the risk of hypertension (HTN) and major adverse cardiac events (MACEs), including acute coronary syndrome, heart failure, and ischemic stroke.Methods Using UK Biobank whole-exome sequencing data from 393,649 European participants, we identified rare (minor allele frequency <0.01) pathogenic variants with predicted high-impact functional consequences in GPCR genes, based on Ensembl Variant Effect Predictor annotations. For missense variants, pathogenicity likelihood scores from AlphaMissense, Mendelian Clinically Applicable Pathogenicity, and Combined Annotation Dependent Depletion were assessed. Multivariable logistic regression models, adjusted for age, sex, BMI, genetic ancestry, and other potential confounders, were conducted to compare RPV prevalence between cases and controls.Results We identified a total of 158 RPVs in SCFA-sensing GPCR genes. The prevalence of RPV carriers was significantly higher in patients with HTN (OR=1.12, P=0.014) and MACEs (OR=1.18, P=0.009) than controls. In single GPCR gene analyses, RPVs in the FFAR2 gene (encoding GPR43) were associated with an increased risk of HTN (OR=1.23, P=0.005). RPVs in the HCAR2 gene (encoding GPR109A) were associated with a markedly increased risk of heart failure (OR=1.57, P=0.012).Conclusions These findings confirm and extend previous results from knockout animal models in a large population-based cohort, highlighting the potential of GPCRs as therapeutic targets for HTN and cardiovascular diseases in humans.Competing Interest StatementThe authors have declared no competing interest.Funding StatementF.Z.M. is supported by a Senior Medical Research Fellowship from the Sylvia and Charles Viertel Charitable Foundation, a National Heart Foundation Future Leader Fellowship (105663), and National Health & Medical Research Council (NHMRC) Emerging Leader Fellowship (GNT2017382). M.S. is supported by a National Heart Foundation Postdoctoral Fellowship (106698).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research has been conducted using the UK Biobank (UKBB) Resource under Application Number 86879. This work uses data provided by patients and collected by the NHS as part of their care and support. The UKBB received ethical approval from the competent Research Ethics Committee (REC reference for UKBB is 11/NW/0382).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis research has been conducted using the UK Biobank Resource under Application Number 86879. This work uses data provided by patients and collected by the NHS as part of their care and support.